Should I buy or sell Sensei Biotherapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNSE shares. View SNSE analyst ratings or view top-rated stocks .

What is Sensei Biotherapeutics' stock price target for 2024?

1 brokers have issued 1-year price objectives for Sensei Biotherapeutics' stock. Their SNSE share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 298.0% from the stock's current price. View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts .

How have SNSE shares performed in 2024?

Sensei Biotherapeutics' stock was trading at $0.6920 at the beginning of the year. Since then, SNSE stock has increased by 45.2% and is now trading at $1.0050. View the best growth stocks for 2024 here .

When is Sensei Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SNSE earnings forecast .

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02.

When did Sensei Biotherapeutics IPO?

Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free SNSE Stock Alerts

$1.00

-0.05 (-4.74%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.00
▼
$1.05
50-Day Range: $0.76
▼
$1.17
52-Week Range: $0.51
▼
$1.93

Volume: 35,642 shs
Average Volume: 66,330 shs
Market Capitalization: $25.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Sensei Biotherapeutics alerts:

Sensei Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 298.0% Upside
$4.00 Price Target
Short Interest: Healthy
0.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.38
Upright™ Environmental Score
News Sentiment: 0.62
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.97) to ($0.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

112th out of 929 stocks

Pharmaceutical Preparations Industry

39th out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
Sensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sensei Biotherapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.96% of the float of Sensei Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sensei Biotherapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sensei Biotherapeutics has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sensei Biotherapeutics does not currently pay a dividend.
Dividend Growth
Sensei Biotherapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sensei Biotherapeutics is -0.38.

2.6

News and Social Media Coverage

News Sentiment
Sensei Biotherapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for SNSE on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.50% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.50% of the stock of Sensei Biotherapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($0.97) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sensei Biotherapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sensei Biotherapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sensei Biotherapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Sensei Biotherapeutics Stock (NASDAQ:SNSE)

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

SNSE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNSE Stock News Headlines

April 12, 2024 | americanbankingnews.com

Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 1.8%

April 9, 2024 | globenewswire.com

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 4, 2024 | uk.investing.com

Sensei Biotherapeutics CFO Erin Colgan to resign

April 4, 2024 | globenewswire.com

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

March 22, 2024 | globenewswire.com

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

March 6, 2024 | globenewswire.com

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trials

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 28, 2024 | globenewswire.com

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

February 9, 2024 | msn.com

Sensei Biotherapeutics Announces Board Member Resignation and Consultant Role

February 9, 2024 | msn.com

Sensei Biotherapeutics Streamlines Board, Appoints Interim Chair

February 7, 2024 | finance.yahoo.com

Sensei Biotherapeutics to Present at Upcoming Conferences

January 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety Data

January 4, 2024 | finance.yahoo.com

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

December 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)

December 4, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy Recommendation

November 7, 2023 | msn.com

Sensei Biotherapeutics GAAP EPS of -$0.28 in-line

November 7, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 7, 2023 | finance.yahoo.com

Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results

November 3, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

October 25, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

October 24, 2023 | bizjournals.com

Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq

October 23, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

September 27, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

September 21, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

September 13, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

See More Headlines

Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNSE
CUSIP: N/A
CIK: 1829802
Web: www.senseibio.com
Phone: 240-243-8000
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +298.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.01%
Return on Assets: -38.58%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 11.92
Quick Ratio: 11.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.60 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 25,070,000
Free Float: 18,678,000
Market Cap: $25.20 million
Optionable: Not Optionable
Beta: 0.16

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. John K. Celebi M.B.A. (Age 52)
President, CEO & Director
Comp: $799.69k
Ms. Erin Colgan (Age 43)
Chief Financial Officer
Comp: $558.83k
Dr. Edward Van der Horst Ph.D. (Age 51)
Chief Scientific Officer
Comp: $444.87k
Ms. Lora Pike
Vice President of Investor Relations & Communications
Mr. Christopher W. Gerry J.D.
Senior VP, General Counsel & Secretary
Ms. Stephanie Krebs M.B.A.
M.S., Chief Business Officer
Dr. Aaron Weitzman FACP
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNSE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings or view top-rated stocks.
What is Sensei Biotherapeutics' stock price target for 2024?: 1 brokers have issued 1-year price objectives for Sensei Biotherapeutics' stock. Their SNSE share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 298.0% from the stock's current price.
View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts.
How have SNSE shares performed in 2024?: Sensei Biotherapeutics' stock was trading at $0.6920 at the beginning of the year. Since then, SNSE stock has increased by 45.2% and is now trading at $1.0050.
View the best growth stocks for 2024 here.
When is Sensei Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SNSE earnings forecast.

How were Sensei Biotherapeutics' earnings last quarter?: Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02.
When did Sensei Biotherapeutics IPO?: Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.
How do I buy shares of Sensei Biotherapeutics?: Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNSE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial